Latest Headlines

Latest Headlines

Athersys tanks as its stem cell therapy flunks a Phase II stroke trial

Athersys' in-development stem cell treatment failed to beat placebo in a Phase II trial on stroke patients, demolishing the company's value as management digs for a positive spin.

MolMed picks up CAR-T asset from hot Italian research institute

MolMed has become the latest to buy its way into the CAR-T race. The deal sees it pick up assets from an immune-gene therapy CAR-CD44v6 project run by a group at San Raffaele Scientific Institute, the Milan-based research center that struck a deal with Biogen in January.

Targacept tanks (again) after its last surviving drug program flops

The litany of clinical trial disasters that has played out at Targacept over the past three years continues this morning with the news that its last remaining pipeline asset failed a Phase I/II study for diabetic gastroparesis. And as has happened so many times before, the biotech's share price took another nasty tumble, dropping 22%.

New data on GW Pharma's cannabis-based epilepsy drug stokes hopes of success

GW Pharmaceuticals' in-development epilepsy drug slashed rates of seizures by more than 50% in a study, a hopeful sign for the cannabis-derived treatment as it works through Phase III.

Bayer hits the gas on its top cancer prospect with Phase III in sight

Bayer is plotting a pair of Phase III trials for its lead oncology treatment, hoping to crack the crowded field of new blood cancer drugs with a targeted therapy of its own.

Rhythm rolls into Phase IIb with an Actavis buyout in the balance

Boston biotech Rhythm is advancing its lead drug into Phase IIb under the eye of Actavis, which has inked a deal to buy the gastrointestinal treatment if it likes what it sees.

Nabriva preps for PhIII antibiotic trial with a $120M VC commitment

A transatlantic group of venture investors crowded into a $120 million venture round for Vienna-based Nabriva Therapeutics, offering enough cash to get started with a Phase III study for a new antibiotic.

Ocular Therapeutix plunges as eye treatment blurs the line in PhIII

Ocular Therapeutix needed a clean sweep in its expansive Phase III program for a postoperative eye treatment in order to set itself up for a clear shot at an FDA approval. But it didn't get it.

Alkermes heads to Phase III with a schizophrenia drug designed to spare the waistline

Alkermes unveiled more positive data for a schizophrenia drug the company believes can treat the disease without spurring weight gain, beating a path to late-stage development.

MorphoSys: That Celgene-abandoned cancer drug isn't dead yet

Germany's MorphoSys is moving on after the surprise cancelation of a Celgene partnership spooked investors and battered the company's share price, with CEO Simon Moroney preaching patience for an early-stage cancer candidate.